Organoids are miniature 3D in vitro structures grown from patient-derived cells that maintain the key features and functions of the originating healthy or diseased tissue.
Drug tests on organoids have demonstrated in many scientific publications to be highly accurate in predicting in vivo drug response.Using QGel for HTS drug screening
QGel ECM formulations are designed to follow you through the entire drug discovery process. Once a synthetic ECM has been identified for a cell type and key physiological feature expression, this formulation can be used in research applications from target identification to clinical development. Packaging formats support exploratory studies on the bench as well as high throughput screening campaigns using existing automation equipment.
TARGET ID & VALIDATION
QGel can be used on the bench in the early phases of drug discovery for exploratory studies to better understand the mechanics of disease. Once a formulation is identified that supports biologically accurate cell behavior, it can be used throughout the entire discovery process.
With an understanding of the mechanics of the disease and a QGel formulation that has been validated to maintain the key features of that disease, QGel assays can be upscaled for high throughput screening campaigns capable of testing vast compound libraries in search of hits.
HIT TO LEAD
Hits that have been identified with the QGel high throughput assays in the lead discovery phase can then be examined more closely with the same formulation back on the bench (e.g. histology studies). QGel can even be used to cast gel discs to initiate tumor formation for implantation into animal models.
The drug discovery process from exploratory research to selecting a drug candidate for clinical development is never routine and requires a lot of back-and-forth from the bench to high throughput screening to animal studies and back to the bench. QGels predictive assays are able to navigate this path with you.
Identifying which patients are most likely to respond to a treatment before enrolling them into a clinical trial is important to the success of any clinical trial. QGel assays can be used to test drug candidates on patient cells in an in vitro platform in order to separate those not likely to show a response from those who are likely to respond positively.
QGel's extracellular matrix analogues are being used in leading cancer centers to validate their use for predictive diagnostic applications. Due to their synthetic composition, they are well suited for clinical decision making. Please contact us in the form below to learn how to incorporate QGel assays in your patient treatment studies.